SenzaGen AB reported consolidated sales results for the first quarter of 2023. Consolidated net sales in the January- March period increased by 36% to SEK 12.3 million driven by strong GARD® sales from new and returning major global customers combined with growth in VitroScreen's innovation services for medical devices, cosmetics and pharmaceuticals.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.7 SEK | +2.39% | +20.69% | +5.77% |
Mar. 25 | Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader | CI |
Mar. 22 | SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.77% | 16.68M | |
-18.16% | 11.13B | |
+58.43% | 3.6B | |
-31.31% | 2.26B | |
-14.31% | 2.16B | |
-26.61% | 1.54B | |
+34.35% | 1.17B | |
-3.28% | 744M | |
-22.75% | 482M | |
-40.20% | 432M |
- Stock Market
- Equities
- SENZA Stock
- News SenzaGen AB
- SenzaGen AB Reports Consolidated Sales Results for the First Quarter of 2023